Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-AnalysisReportar como inadecuado




Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Digestive Diseases and Sciences

, Volume 61, Issue 11, pp 3108–3117

First Online: 12 September 2016Received: 14 April 2016Accepted: 23 August 2016DOI: 10.1007-s10620-016-4291-2

Cite this article as: He, QF., Zhang, QF. & Zhang, DZ. Dig Dis Sci 2016 61: 3108. doi:10.1007-s10620-016-4291-2

Abstract

BackgroundSofosbuvir and ledipasvir with or without ribavirin RBV regimens SLR vs. SL have exhibited promising results for the treatment of patients with hepatitis C virus HCV genotype 1 infection.

AimTo comprehensively compare the efficacy and safety of the SL and SLR regimen for the treatment of chronic HCV genotype 1 infections.

MethodsThe Cochrane Library, PubMed, Web of Science, and EMBASE databases were searched. Only RCTs that compared the efficacy and safety of SL or SLR regimen for the treatment of chronic HCV genotype 1 infection were included. The primary outcome measures were the sustained virological response weeks 12 SVR12 post-treatment and adverse events AEs.

ResultsSeven studies comprising 2601 patients were included. Compared with the SL regimen, SLR yielded a similar probability of having an SVR12 RR 1.002, 95 % CI 0.998, 1.017, P = 0.780. Based on subgroup analyses, the addition of RBV to the 8-week SL regimen improved the SVR12 rate. However, the SLR regimen for 12 or 24 weeks did not show a superior SVR12 rate regardless of treatment history and the presence or absence of cirrhosis. The pooled incidence of AEs was higher in patients that received the SLR treatment regimen RR 1.140, 95 % CI 1.095, 1.187, P = 0.000.

ConclusionsThe 12-week or 24-week SL regimen with a low incidence of AEs is as effective and well tolerated as the SLR regimen for the treatment of patients with chronic HCV genotype 1 infection.

KeywordsGenotype 1 hepatitis C Sofosbuvir Ledipasvir Ribavirin Efficacy Safety Qiu-Feng He and Qiong-Fang Zhang have contributed equally to the article.

Download fulltext PDF



Autor: Qiu-Feng He - Qiong-Fang Zhang - Da-Zhi Zhang

Fuente: https://link.springer.com/







Documentos relacionados